Menu
Menu
Boston, MA, and Rolle, Switzerland, February 10, 2026 – SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced the addition of two of the largest U.S. healthcare systems to its network.
The two new institutions, which collectively analyze millions of genetic samples annually, include one of the leading nonprofit, multi-region integrated healthcare systems in the U.S. and a top 10 U.S. health system laboratory. Together, these institutions will leverage the AI-native, cloud-based SOPHiA DDM™ to analyze complex genomic data at scale.
By adopting SOPHiA DDM™, the two institutions will initially launch genomic testing for up to 60,000 patients annually across the West Coast and Midwest, enabling faster diagnosis and more personalized care for individuals living with hereditary cancers and rare diseases.
Both health systems will utilize SOPHiA DDM™ for Enhanced Exome, an AI-driven analytics application that supports comprehensive full-exome analysis for over 20,000 genes while enabling the ability to dive deeper into clinically relevant regions. With these capabilities directly embedded into their laboratory workflows, the institutions aim to expedite testing turnaround times, streamline operational costs, and expand internal research and innovation initiatives.
John Carey, Managing Director, North America, SOPHiA GENETICS, said: “Partnering with two of the largest health systems in the U.S. underscores the growing need for AI-powered genomic solutions capable of addressing increasingly complex use cases that can scale without adding operational burden. Combining advanced bioinformatics, the collective knowledge of a global community, and streamlined workflows, our AI enables healthcare institutions to unlock deeper insights.”
Going forward, this collaboration positions both organizations with a scalable foundation to support future expansion of AI-driven precision medicine. Each year, these organizations serve a combined population of nearly one million cancer and rare disorder patients nationwide.
SOPHiA GENETICS continues to strengthen its presence in the United States while supporting leading healthcare institutions across some of the most complex areas of precision medicine. The expansion in the region reinforces the company’s mission to democratize data-driven medicine by equipping researchers and clinicians with AI-powered solutions that accelerate healthcare innovation and research.
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com or connect on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
